BioSpace News Archive

Phio Pharmaceuticals, a clinical stage biotechnology company whose proprietary INTASYL™ RNAi platform technology is designed to make immune cells more effective in killing tumor cells, announced that its Principal Executive Officer and Executive Chairman, Robert Bitterman, will be a featured speaker at the Entrepreneurial Showcase at the Dermatology Summit in San Francisco on January 8th.

Harmony Biosciences Holdings, Inc., a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases, announced that John C. Jacobs is stepping down as President and Chief Executive Officer and a member of the Board of Directors to pursue another opportunity.

Intergalactic Therapeutics, a company focused on transforming medicine through non-viral gene therapy, announced the appointment of Theresa G.H. Heah, M.D., M.B.A., as Chief Executive Officer.

IRLAB Therapeutics AB, a company discovering and developing novel treatments for the most troublesome symptoms of Parkinson’s disease, announced that the company will participate in the 6th Neuroscience Innovation Forum hosted by Sachs Associates.

Regulatory News: Transgene announces it has received clinical trial application approval from the French National Agency for the Safety of Medicines and Health Products to proceed with a Phase I clinical trial of TG6050, a novel oncolytic virus that will be administered intravenously in patients with advanced non-small cell lung cancer.

ConcertAI, LLC today announced the appointment of Claudio D’Ambrosio, PhD, as its first Chief Revenue Officer.

Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today provided a business update and announced strategic objectives and expected milestones for 2023.

Nabriva Therapeutics plc (NASDAQ: NBRV) today announced that, after an assessment of strategic options, its Board of Directors approved a plan to preserve cash in order to adequately fund an orderly wind down of the Company’s operations.

atai Life Sciences announced that, while PCN-101 (R-ketamine) demonstrated signals of efficacy across all timepoints out to two weeks, Perception Neuroscience’s Phase 2a clinical trial did not meet its primary endpoint of a statistically significant change from baseline in participants’ MADRS (Montgomery-Åsberg Depression.

CASI Pharmaceuticals, Inc. announces that the China National Medical Products Administration (NMPA) has approved the Company’s Clinical Trial Application (CTA) for CB-5339, a first-in-class VCP/p97 inhibitor from Cleave Therapeutics.